ARID1A and neoplasm: Additionally, when ARID1A KO ES2 tumors were treated with ERKi (cohort: ES2 AKO ERKi), a similar reduction in tumor growth was observed compared to the untreated cohort (ES2 AKO UT) (Fig. 4c).